Skip to main content
main-content

Expert opinion

20-06-2019 | Systemic lupus erythematosus | Highlight | Article

Systemic lupus erythematosus: Novel therapies and targeted treatments

Andrea Fava and George Stojan review new strategies and agents for the treatment of systemic lupus erythematosus that have most recently showed promise in clinical trials.

12-04-2019 | Gout | Editorial | Article

Using genetic studies to assess the impact of hyperuricemia in cardiometabolic and chronic kidney disease

Editorial Board member Fernando Pérez-Ruiz discusses the impact of hyperuricemia in cardiometabolic and chronic kidney disease, focusing on the role of genetic studies in showing a causal association between these conditions.

27-03-2019 | Juvenile idiopathic arthritis | Editorial | Article

Temporomandibular joint involvement in juvenile idiopathic arthritis: Diagnosis and management

The authors provide an overview of temporomandibular joint involvement in children with juvenile idiopathic arthritis, including imaging methods for diagnosis, clinical examination recommendations, and treatment options.

18-03-2019 | Juvenile idiopathic arthritis | Editorial | Article

Enhancing clinical assessment with ultrasonography in juvenile idiopathic arthritis

Johannes Roth outlines the rationale behind the use of musculoskeletal ultrasonography in children with juvenile idiopathic arthritis, including enhancement of clinical assessment as part of a treat-to-target approach.

01-03-2019 | Juvenile idiopathic arthritis | Editorial | Article

The microbiota in juvenile idiopathic arthritis: What’s wrong, and what can we do?

In this editorial, Matthew Stoll explores the role of the microbiota in the pathogenesis of juvenile idiopathic arthritis, as well as current research into therapeutic alterations of the microbiome.

18-02-2019 | Osteoporosis | Editorial | Article

Osteoporosis therapy: Drug holiday or not?

Malachi McKenna explains the risks of long-term bisphosphonate therapy in patients with osteoporosis, and the rationale for a drug holiday. He also compares bisphosphonates with denosumab, and explains why denosumab should not be followed by a drug holiday.

12-02-2019 | Cardiovascular disease | Editorial | Article

Cardiovascular risk management in arthritis: Why still a bridge too far?

Cardiovascular disease is the main cause of death in patients with rheumatoid arthritis. In this editorial Michael Nurmohamed discusses the EULAR recommendations for cardiovascular risk management, focusing on the role of the rheumatologist.

11-02-2019 | Rheumatoid arthritis | Editorial | Article

20 years of TNF inhibitors in rheumatoid arthritis

Understanding and treatment of rheumatoid arthritis has changed dramatically over the past two decades. Peter Taylor describes the impact of biologic tumor necrosis factor inhibitors on the management of this disease.

29-01-2019 | Lupus nephritis | Editorial | Article

Emerging therapies for lupus nephritis

Lupus nephritis is the most common organ-threatening complication of systemic lupus erythematosus, and current treatment regimens are only partially effective and are potentially toxic. In this editorial, the authors focus on emerging therapeutics to treat this disease.

11-01-2019 | Psoriatic arthritis | Editorial | Article

Screening psoriasis patients for development of psoriatic arthritis

Vinod Chandran discusses recent developments in screening tools for identifying patients with psoriatic arthritis, and those who are at high risk for developing this disease.

14-11-2018 | Infection | Editorial | Article

Minimizing infection risk with biologic therapy

While the development of biologics has revolutionized treatment of rheumatic diseases, these agents can lead to immunosuppression and increased infection risk. Eoin Feeney discusses the role of screening and treatment for latent infection prior to therapy, vaccination timing, and travel risks in patients taking these medications.

18-10-2018 | Microbiome | Editorial | Article

Why every rheumatologist should understand the microbiome

James Rosenbaum and Mark Asquith discuss how the microbiome interacts with the immune system, how this may induce inflammation, and how the microbiome could be used as a therapeutic target for rheumatic diseases.

18-10-2018 | Infection | Editorial | Article

Vaccination in children and adolescents with rheumatic conditions

In this editorial, the authors discuss the risks of live vaccination in children taking antirheumatic medications and how to manage these, as well as how health authorities can address decreasing vaccination coverage of the general public.

16-10-2018 | Pregnancy | Editorial | Article

Planning and managing pregnancy in lupus patients

Megan Clowse discusses the importance of planning pregnancy in patients with lupus to avoid high-risk pregnancy, and outlines strategies to manage active lupus during pregnancy.

10-10-2018 | Mental health | Editorial | Article

Why depression and anxiety matter in patients with inflammatory arthritis

Advisory Board member Susan Bartlett discusses the prevalence of mental health comorbidities in patients with inflammatory arthritis, and their impact on disease symptoms and quality of life.

27-09-2018 | Fibromyalgia | Editorial | Article

Treatment and outcomes of pediatric fibromyalgia: More than resolving pain

David Sherry discusses various pharmacologic and non-pharmacologic treatments for management of pediatric fibromyalgia, and outlines the impact of an interdisciplinary approach on physical function, mental health and pain outcomes in these patients.

20-07-2018 | Granulomatosis with polyangiitis | Editorial | Article

The ongoing evolution of remission maintenance strategies for granulomatosis with polyangiitis

Eric J Gapud and Philip Seo summarize the key milestones in management of severe granulomatosis with polyangiitis, and evaluate the possibility of long-term reduced intensity or drug-free remission for some patients.

22-05-2018 | Gout | Editorial | Article

Audits on gout management: Far from excellence, but working on it

Editorial Board member Fernando Pérez-Ruiz analyzes recent audits on the management of gout in primary and secondary care, and suggests strategies to improve clinical practice.

22-03-2018 | Biosimilars | Editorial | Article

Biosimilars: The price is not right

Editorial Board member Marc Cohen analyzes the various economic factors influencing the price of biosimilars over recent years in rheumatology, focusing on the United States healthcare system.

21-02-2018 | Gout | Editorial | Article

Gout therapies and cardiovascular risk

Editorial Board member Fernando Pérez-Ruiz highlights recent clinical trials evaluating the effect of febuxostat on risk of cardiovascular comorbidities, and discusses alternative treatments for gout patients with cardiovascular disease.

Image Credits